Company intelligence / Profile preview
Tivorsan Pharmaceuticals
Providence, RI, USAtivorsan.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tivorsan Pharmaceuticals developed TVN‑102, a recombinant human biglycan protein for treating Duchenne muscular dystrophy. The company received FDA orphan drug designation for this program and completed preclinical studies showing improved muscle health in animal models. As of the last updates, they were preparing for Phase 1 trials but there are no public records indicating progression beyond preclinical or early IND-enabling work.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Recombinant proteinProteinBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Parent Project Muscular Dystrophy (PPMD) [grant funding partner]Muscular Dystrophy Association (MDA) [grant funding partner/investor via MDA Venture Philanthropy funder group]
Beyond the preview
Go deeper on Tivorsan Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tivorsan Pharmaceuticals.